Drug Overview

Selective estrogen receptor degrader LSZ102 is an experimental, laboratory-made medication created to fight a specific type of breast cancer. It belongs to a modern family of cancer-fighting pills designed to seek out and destroy the hormone receptors that certain tumors use to fuel their growth.

Because it is an investigational drug, it is not available at your standard local pharmacy. Patients can only receive this medication if they are participating in approved medical research studies (clinical trials).

• Generic name: Selective estrogen receptor degrader LSZ102 (also known as LSZ102)
• US Brand names: None (Investigational drug)
• Drug Class: Oral Selective Estrogen Receptor Degrader (SERD), Small-molecule inhibitor
• Route of Administration: Oral (taken by mouth as a tablet or capsule)
• FDA Approval Status: Investigational (Not currently approved by the FDA for standard medical use)

What Is It and How Does It Work? (Mechanism of Action)

LSZ102 is a highly specialized Targeted Therapy and possesses Smart Drug characteristics. Older hormone therapies simply block hormones from feeding the cancer, but they leave the cancer’s “feeding tubes” intact. This drug goes a step further by completely destroying the feeding tubes.

To understand how it works at the molecular level, imagine that many breast cancer cells have receiver antennas on their outer surface called Estrogen Receptor alpha. When the body’s natural estrogen connects to these antennas, it sends a powerful signal down into the cell. This signal tells the cancer cell to grow, divide, and spread.

LSZ102 works by finding and binding tightly to these estrogen antennas. When the drug attaches, it forces the antenna to change its physical shape. The cancer cell suddenly recognizes this bent antenna as damaged trash. The cell’s internal garbage disposal system (called the proteasome) then completely destroys and recycles the receptor. Without these estrogen antennas, the cancer cell can no longer hear the growth signals, forcing the tumor to stop dividing.

FDA Approved Clinical Indications

Because this medication is still classified as investigational, it does not have official FDA-approved indications for the general public. However, researchers are studying it in clinical trials for the following specific areas:

Oncological uses

• Investigational treatment for advanced or metastatic breast cancer that is Estrogen Receptor-positive and HER2-negative.
• Investigational treatment for breast cancer in patients whose tumors have stopped responding to older hormone therapies due to genetic changes (specifically, ESR1 mutations).

Non-oncological

• There are currently no non-oncological uses for this medication.

Dosage and Administration Protocols

Because LSZ102 is an experimental drug, the exact amount a patient takes depends entirely on the rules of their specific clinical trial. It is often tested alone, or combined with other targeted therapies like ribociclib or alpelisib to make it work better. The table below outlines the standard dosing framework used in recent Phase 1 human research studies.

Dose Adjustments

Because this medication can cause stomach issues and is processed by the liver, careful dose adjustments are required. If a patient experiences severe stomach upset, diarrhea, or routine blood tests reveal an increase in liver enzymes, the clinical trial doctors will lower the dose or temporarily pause the medication until the body heals. Patients with severe hepatic (liver) insufficiency or renal (kidney) insufficiency may require customized, lower starting doses.

Clinical Efficacy and Research Results

Clinical research data from recent Phase 1 trials published between 2020 and 2025 have provided numerical data on how well LSZ102 works for patients with advanced breast cancer who have already tried many other treatments.

When LSZ102 was used completely on its own, it showed modest results. The objective response rate (the percentage of patients whose tumors shrank significantly) was 1.3 percent, and the median time before the disease progressed was 1.8 months.

However, researchers found that the drug worked much better when combined with other targeted therapies. When LSZ102 was combined with a drug called ribociclib, the objective response rate jumped to 16.9 percent. The clinical benefit rate (the percentage of patients whose cancer either shrank or stopped growing for a long period) reached over 35 percent. For these patients, the median time before the disease progressed was extended to 6.2 months. These numbers proved to researchers that combining an oral SERD like LSZ102 with other targeted drugs is a very promising strategy for overcoming hard-to-treat breast cancers.

Safety Profile and Side Effects

Like all medications that alter the body’s hormones and target cancer cells, LSZ102 can cause side effects. Patients in clinical trials are monitored very closely by their oncology teams.

Black Box Warning

Because this drug is investigational and not available on the open market, it does not currently carry an official FDA Black Box Warning.

Common side effects

These side effects were reported in greater than 10 percent of patients during clinical trials:

• Nausea and upset stomach
• Diarrhea
• Vomiting
• Feeling extremely tired or weak (fatigue)
• Decreased appetite

Serious adverse events

• Severe gastrointestinal distress (constant vomiting or diarrhea) that can lead to dangerous dehydration.
• Increased liver enzymes (hepatotoxicity) indicating liver stress.
• When combined with other drugs like alpelisib, the risk of serious side effects (like high blood sugar or severe skin rashes) increases.

Management strategies

Patient safety relies on careful and fast management of side effects. Because stomach issues are the most common problem, doctors quickly prescribe anti-nausea medicines and anti-diarrheal pills for patients to take at home. Patients are strongly advised to drink plenty of fluids. To protect the liver, patients undergo frequent blood tests; if liver enzymes rise to concerning levels, the medical team will immediately pause the medication.

Research Areas

While LSZ102 is not currently used directly with stem cell transplants, it plays a major role in genetic cancer research. Cancer cells are very smart and often mutate to survive standard treatments. They form “cancer stem-like cells” that hide and wait to regrow. Many of these stubborn cells survive by mutating their estrogen receptors (known as an ESR1 mutation). By studying how LSZ102 destroys both normal and mutated estrogen receptors, scientists are learning how to completely cut off the energy supply to these hidden cancer cells, preventing the tumor from returning in the future.

Patient Management and Practical Recommendations

Participating in a clinical trial for an investigational hormone therapy requires strict teamwork between the patient and the healthcare team.

Pre treatment tests to be performed

• A tumor biopsy or a “liquid biopsy” (a special blood test) to confirm the cancer is Estrogen Receptor-positive and to check for ESR1 mutations.
• Comprehensive metabolic panels to establish a baseline for liver and kidney function.
• A complete blood count to evaluate overall health before starting the trial.
• An electrocardiogram to check the electrical rhythm of the heart, especially if the drug is being combined with ribociclib.

Precautions during treatment

Patients must be highly vigilant about their digestion and hydration. Because diarrhea and vomiting are common, dehydration can happen quickly and cause kidney damage if ignored.

Do’s and Don’ts list

• Do take the medication at the same time every day, exactly as instructed by your trial doctor.
• Do drink plenty of water and clear liquids every day.
• Do call your medical team immediately if you cannot keep liquids down or if you have severe diarrhea.
• Don’t take any other hormone-altering medications, estrogen creams, or birth control pills without asking your trial doctor first.
• Don’t take any over-the-counter vitamins or herbal products without getting explicit permission from your oncologist, as they can interfere with how your liver processes the experimental drug.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. Selective estrogen receptor degrader LSZ102 is an investigational medication and is not approved by the Food and Drug Administration to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional or your clinical trial oncologist before making any decisions regarding your medical treatment, managing side effects, or participating in a clinical research study.